A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers
A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers
Active, not recruiting · NCT06496568 · Registry updated 2026-08-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers | PIK3CA-Mutated Cancers | Active, not recruiting | Phase 1 | 2026-08-20 | NCT06496568 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Hoffmann-La Roche | 280 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| BC Cancer Vancouver Centre | Vancouver | Canada | 2 |
| Jewish General Hospital | Montreal | Canada | 130 |
| Princess Margaret Cancer Center | Toronto | Canada | 30 |
| Samsung Medical Center | Seoul | South Korea | 375 |
| Vanderbilt-Ingram Cancer Ctr | Nashville | United States | 1 |